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Purpose/Objective: High risk of tumour regrowth following 
treatment with radiation therapy for a subset of prostate 
cancer patients highlights the need for prognostic 
biomarkers. miRNAs are key regulators of cancer cell 
behavior that could control their response to ionizing 
radiation. Owing to their availability in tissues, serum and 
urine, miRNAs are ideal candidates for the development of 
novel biological tests. This study aimed to identify key 
miRNAs associated with a radioresistant phenotype in cancer 
cells, as a prerequisite for the future development of a novel 
pre-treatment assay for the identification of radiotherapy 
prostate cancer patients at risk of biochemical failure.  
Materials and Methods: A dual approach was used for the 
identification of candidate miRNAs associated with 
radioresistance: (1) an isogenic radiation resistant model was 
generated using the 22Rv1 (primary) prostate cancer (CaP) 
cell line through weekly exposure to 2-Gy fractionated 
ionising radiation. (2) chronically hypoxic 22Rv1 cells (48hrs) 
were used as an additional model for radioresistance. miRNA 
profiling of radioresistant and wild type cells was performed 
using the Exiqon miRCURY array and overlapping 
differentially expressed miRs were identified. 
Results: Following a cumulative total dose of 60Gy, the 
radiation survival curve of the resulting subline RR22Rv1 was 
associated with a significant increase in clonogenic survival 
(1.3 fold increase in survival after 2Gy and 2.2 fold increase 
after 10Gy), when compared to both parent 22Rv1 and aged-
matched controls. The RR22Rv1 cell line is associated with 
decreased sensitivity to DNA damage (comet assay), 
enlargement of the S-phase cell population (PI staining) but 
no evidence for expansion of the senescent cell fraction (β-
Gal assay). miRNA profiling identified 105 significantly 
differentially expressed miRNAs in RR22Rv1, when compared 
to the parent and age-matched control 22RV1 cells. A total of 
12 miRNA were differentially expressed in chronically hypoxic 
compared to normoxic 22Rv1 cells. Three candidate miRNAs 
were associated with a radioresistant phenotype across the 
models: miR200a, miR210 and miR4284. Functional validation 
of these candidates is currently under way.  
Conclusions: This study demonstrates a role for miRNAs in 
the radioresponse of prostate cancer cells and highlights 
their potential for the development of novel prognostic 
biomarkers for radiotherapy prostate cancer patients. 
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Purpose/Objective: Organ preservation of muscle invasive 
bladder cancer after external radiotherapy is an important 
outcome for those patients who are unresectable or chose 
not to have cystectomy. Geometric uncertainties due to 
pelvic organ movement and internal bladder motion present 
a major challenge in defining the true extent of the bladder 
on computerised tomography (CT) images. This is 
complicated further by a lack of soft tissue contrast on CT 
images at the bladder prostate junction (BPJ) where 
significant clinical experience is required to interpret and 
ensure that the dose to the prostate remains within 
acceptable limits. The aim of this study was to investigate 
the use of image analysis for enhancing the BPJ on CT images 
used for RT planning and thereby allow simple image 
thresholding to produce reliable estimates of the clinical 
target volume (CTV). This has application in adaptive 
radiotherapy for automatically defining the bladder volume 
on cone-beam CT (CBCT). 
Materials and Methods: Image data was acquired on a single 
slice General Electric (GE) HiSpeed Fx/i CT scanner (GE 
Medical Systems, Milwaukee, WI, USA) with 0.977 mm pixel 
resolution in the transaxial plane and a 2048 grey-level 
range. Five bladder cancer patients treated with a radiation 
dose of 52.5 Gy (20 fractions/4 weeks) at the Edinburgh 
Cancer Centre (ECC), were included in this study. Each 
patient received a 3 mm thick CT scan, with a presumed 
empty bladder, which was used to: define the target volume; 
define critical anatomical structures; determine the optimum 
radiation beam arrangement; and estimate the dose. Where 
possible CT scanning was performed twice weekly and repeat 
CT scans registered against bone on the corresponding 
planning scan using the GE Advantage fusion software. This 
resulted in 36 data sets, which were contoured by an 
experienced radiation oncologist and image analysis methods 
used to produce a new image set containing the enhanced 
BPJ.  
Results: 
 
 
On the 36 new data sets a threshold was set to extract the 
CTV, which included the bladder and BPJ. The variability 
